Daily Ards Research Analysis
Across ARDS research today, evidence for optimal PEEP in COVID-19 ARDS remains insufficient despite a registered systematic review, underscoring the need for individualized, physiology-guided trials. A prospective study links higher C5aR2 (a complement receptor) to better recovery and identifies the C5a/C5aR2 ratio as a prognostic marker, while a multicenter cohort connects CT-defined lung damage and patterns with D-dimer and worse outcomes.
Summary
Across ARDS research today, evidence for optimal PEEP in COVID-19 ARDS remains insufficient despite a registered systematic review, underscoring the need for individualized, physiology-guided trials. A prospective study links higher C5aR2 (a complement receptor) to better recovery and identifies the C5a/C5aR2 ratio as a prognostic marker, while a multicenter cohort connects CT-defined lung damage and patterns with D-dimer and worse outcomes.
Research Themes
- Individualized ventilator strategies and PEEP optimization in ARDS
- Complement biology (C5a–C5aR2 axis) as a prognostic pathway
- Imaging–coagulation interfaces (CT severity and D-dimer) for risk stratification
Selected Articles
1. Determination of positive end-expiratory pressure in COVID-19-related acute respiratory distress syndrome: A systematic review.
This PROSPERO-registered systematic review (CRD42021260303) screened 16,026 records, evaluated 119 full texts, and included 12 observational studies on PEEP strategies in COVID-19 ARDS. Evidence did not support definitive recommendations for higher vs lower PEEP or standardized vs individualized PEEP titration. The authors call for well-designed platform trials to test individualized, physiology-guided PEEP across ARDS phenotypes and stages.
Impact: Clarifies the limits of existing evidence and redirects the field toward individualized, physiology-based PEEP research rather than one-size-fits-all protocols.
Clinical Implications: Avoid rigid adherence to high- or low-PEEP tables in COVID-19 ARDS; integrate bedside physiology and recruitability assessment while awaiting trials. Prioritize enrollment in platform studies testing individualized titration.
Key Findings
- Screened 16,026 records, assessed 119 full texts, and included 12 observational studies on PEEP in COVID-19 ARDS.
- No conclusive advantage of higher vs lower PEEP or standardized vs individualized PEEP titration was identified.
- Calls for platform trials to test individualized, physiology-guided PEEP across ARDS phenotypes, severities, and stages.
Methodological Strengths
- Registered protocol (PROSPERO: CRD42021260303) with comprehensive multi-database search strategy
- Clearly stated clinical questions comparing higher vs lower and standardized vs individualized PEEP
Limitations
- Only observational studies were available; heterogeneity precluded meta-analysis
- Findings limited to COVID-19 ARDS and may not generalize to non-COVID ARDS phenotypes
Future Directions: Conduct platform RCTs incorporating recruitability and lung mechanics to individualize PEEP; include diverse ARDS etiologies and disease stages.
BACKGROUND: The impact of high positive end-expiratory pressure (PEEP) ventilation and the optimization of PEEP titration in COVID-19-induced acute respiratory distress syndrome (ARDS) continues to be a subject of debate. In this systematic review, we investigated the effects of varying PEEP settings on patients with severe ARDS primarily resulting from COVID-19 (C-ARDS). OBJECTIVES: Does higher or lower PEEP improve the outcomes in COVID-19 ARDS? Does individually titrated PEEP lead to better outcomes compared with PEEP set by standardised (low and high ARDS network PEEP tables) approaches? Does the individually set PEEP (best PEEP) differ from PEEP set according to the standardised approaches (low and high ARDS network PEEP tables)? DESIGN: Systematic review of observational st
2. Role of C5aR2 in prognosis of patients with acute respiratory distress syndrome through negative modulation of C5a: A prospective observational study.
In a prospective cohort of 64 ARDS patients, the C5a/C5aR2 ratio outperformed individual markers in predicting poor outcomes (AUC 0.707; specificity 78.1%). Higher C5aR2 levels were associated with recovery (OR 0.225), while a higher C5a/C5aR2 ratio predicted non-recovery (OR 3.281). Steroid therapy correlated with better recovery among patients with a high C5a/C5aR2 ratio.
Impact: Introduces a biologically plausible prognostic axis (C5a–C5aR2) in ARDS with potential to inform patient stratification and therapeutic decisions.
Clinical Implications: Consider complement profiling in moderate-to-severe ARDS to refine prognosis; patients with high C5a/C5aR2 ratios may particularly benefit from corticosteroids, pending validation.
Key Findings
- C5a/C5aR2 ratio showed the best discrimination for poor prognosis (AUC 0.707; specificity 78.1%) compared with C5aR2 (AUC 0.699) and C5a (AUC 0.511).
- Higher C5aR2 levels were associated with better recovery (OR 0.225; p=0.009), while a higher C5a/C5aR2 ratio predicted non-recovery (OR 3.281; p=0.036).
- Corticosteroid use was associated with better recovery among patients with a high C5a/C5aR2 ratio (OR 0.104; p=0.007).
Methodological Strengths
- Prospective cohort design with predefined biomarker measurements using ELISA
- Use of AUROC and multivariable regression to assess prognostic performance and associations
Limitations
- Single-year, relatively small sample size (n=64) limits generalizability
- Potential residual confounding; external validation cohorts are lacking
Future Directions: Validate C5aR2 and the C5a/C5aR2 ratio in larger, multicenter cohorts; test biomarker-guided corticosteroid strategies in randomized trials.
OBJECTIVE: Diverse inflammatory pathology is involved in acute respiratory distress syndrome (ARDS). This study aimed to assess the role of complement component fragment 5a (C5a) receptor 2 (C5aR2) in prognosis of patients with ARDS. METHODS: A total of 64 adult patients diagnosed with ARDS were prospectively recruited to the study over a period of one year after obtaining the informed consent. The serum C5a and C5aR2were determined using ELISA Kit sandwich method. Area under receiver operating characteristic (AUROC) was used to analyse the prognostic performance of C5a, C5R2, and C5a/C5R2 ratio using MedCalc. The relationship of these biomarkers with the parameters of poor prognosis (non-recovery, hospitalization, ventilation and ICU admission) was analysed through regression using SPSSv20. RESULTS: The mean age of the included participants was 49.17 (SD:14.81) years. C5a/C5aR2 ratio had better discrimination (AUC: 0.707 vs 0.699 vs 0.511) and higher specificity (78.1 vs 71.9 vs 3.1) than C5R2 and C5a in predicting the poor prognosis among ARDS patients. The increased level of C5aR2 (OR: 0.225; p = 0.009) was significantly associated with better recovery and the high C5a/C5aR2 ratio (OR: 3.281; p = 0.036) was significantly associated with non-recovery in moderate to severe patients. Additionally, steroid treatment significantly associated with better recovery in patients with a high C5a/C5aR2 ratio (OR: 0.104; p = 0.007). CONCLUSION: The current evidence indicates that a higher levels of C5aR2 significantly associated with better recovery, whereas high levels of C5a/C5aR2 significantly associated to poor prognosis in moderate to severe ARDS patients. However, adequately powered studies are required to confirm these findings in future.
3. Tomographic features of lung damage associate with D-Dimer levels and further clinical outcome in patients with acute respiratory distress syndrome due to COVID-19.
In a prospective multicenter cohort (n=104) of COVID-19 ARDS, greater CT-quantified lung involvement and late consolidation patterns correlated with higher D-dimer levels. Extent of involvement predicted longer hospitalization, increased mechanical ventilation need, and higher mortality; late consolidation was especially linked to ventilation requirement.
Impact: Bridges imaging severity, coagulation biomarkers, and clinical outcomes, offering pragmatic risk stratification signals early in the ARDS course.
Clinical Implications: Use CT extent and presence of late consolidation alongside D-dimer to identify high-risk patients who may require closer monitoring and early escalation of supportive care.
Key Findings
- Greater CT-quantified lung involvement and late consolidation correlated with higher D-dimer levels.
- Extent of involvement associated with longer hospitalization, higher need for mechanical ventilation, and increased mortality (HRs reported, p<0.01).
- Late consolidation pattern was particularly associated with need for mechanical ventilation (HR 0.23; p<0.01).
Methodological Strengths
- Prospective, multicenter design with standardized CT quantification and expert radiology assessment
- Linkage of imaging biomarkers with coagulation markers and hard clinical outcomes
Limitations
- COVID-19–specific cohort from early pandemic may limit generalizability to current variants and non-COVID ARDS
- Modest sample size (n=104) with potential residual confounding
Future Directions: Validate CT–D-dimer risk models in broader ARDS populations and test whether imaging-guided anticoagulation or ventilatory strategies improve outcomes.
BACKGROUND: Rapid progression of symptoms and development of Acute Respiratory Distress Syndrome (ARDS) frequently occurred during COVID-19 pandemic, while CT-Scan was useful to assess severity of lung damage, with classic patterns like early Ground Glass Opacity and/or late consolidation. Likewise, lung injury has been related to activation of the coagulation-fibrinolysis systems and pro-inflammatory mediators; where D-Dimer acquires prognostic relevance. The present study aimed to evaluate whether the extent of lung involvement and pattern of lung injury, as determined by chest CT-scan, are related with D-Dimer; and further impact clinical prognosis in patients with ARDS due to COVID-19. METHODS: Longitudinal, prospective, observational, multi-center study. Patients diagnosed with ARDS due to COVID-19, without previous lung damage, clotting disorder and/or anticoagulants use, who were attended at the Intensive Care Unit and Internal Medicine Department from March to June 2020. Tomographic extent of lung involvement was analyzed by image software, as well as damage patterns, assessed by experienced radiologists. Endpoints included relation of lung injury with coagulopathy markers like D-Dimer, and prognostic outcome including mortality, mechanical ventilation and hospitalization time. RESULTS: One-hundred and four patients mean aged 55 years old, 66% males, main comorbidities obesity, hypertension and diabetes mellitus. Larger lung damage was associated with older age, male gender and higher pro-inflammatory mediators like leukocytes and ferritin; whilst consolidation pattern was related to higher Body Mass Index. Higher values of D-Dimer were related either to a larger extent of lung involvement or late consolidation pattern. In addition, the extent of lung involvement was related with longer hospital stay, higher requirement of mechanical ventilation (HR 0.12, p < 0.01) and mortality rate (HR 0.13, p < 0.01); whereas late consolidation was mainly associated with requirement of mechanical ventilation (HR 0.23, p < 0.01). CONCLUSION: Tomographic extent of lung involvement and the pattern of lung injury are related with coagulopathy severity markers like D-Dimer, and own prognostic clinical ability in ARDS.